GLP-1R激动剂的心理作用
Loredana Bucciarelli1, Vincenzo Cimino2, Bernardo Dell'Osso3
1Pio Albergo Trivulzio, Milan, Italy; International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, Università di Milano, Italy.
Pharmacological research
|November 18, 2025
概括
用于糖尿病和肥胖症的葡萄糖类-1受体激动剂 (GLP-1RAs) 显示出治疗抑郁症和焦虑症等心理健康状况的新兴潜力. 需要进一步的研究来证实这些有希望的神经精神病学益处.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 精神病学是一个精神病学.
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是已确立的2型糖尿病和肥胖症的治疗方法.
- 新出现的证据表明GLP-1RAs可能通过中央GLP-1受体具有神经精神和神经保护作用.
研究的目的:
- 审查关于GLP-1RA在各种神经精神疾病和物质使用障碍中的使用的临床前,临床和现实世界的证据.
- 探索这些影响背后的潜在机制.
主要方法:
- 关于人体研究和翻译模型的综合文献综述.
- 专注于包括抑郁,焦虑,暴饮暴食障碍,认知障碍,痴呆和物质使用障碍在内的疾病.
主要成果:
- 初步发现表明GLP-1RA在几个神经精神疾病中具有潜在的益处.
- 报告的机制包括神经炎症,神经递质系统和奖励通路的调节.
结论:
- GLP-1RAs显示出作为一种新的治疗方法,可以弥合代谢和心理健康护理的潜力.
- 进一步强大的随机试验与标准化精神药物终点是必要的,以验证这些发现.
相关概念视频
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
860
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
860
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K


